DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Micardis® (Drug); MicardisPlus® (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

The primary objective is to evaluate the effect of the treatment with Micardis or MicardisPlus on blood pressure. Secondary objectives are the effect of Micardis / MicardisPlus on metabolic parameters (triglycerides, cholesterol, blood glucose and HbA1c) in patients with essential hypertension and diabetes mellitus

Clinical Details

Official title: Micardis / MicardisPlus Monitoring of Morning Hypertension and Metabolism II

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Change from Baseline in systolic blood pressure (SBP)

Change from Baseline in diastolic blood pressure (DBP)

Secondary outcome:

Assessment of efficacy by investigator on a 6-point scale

Assessment of metabolic effect on a 4-point scale

Change from Baseline in laboratory parameters

Assessment of tolerability by investigator on a 5-point scale

Number of patients with adverse events

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age > 18 years

- Hypertension

- Diabetes mellitus

Exclusion Criteria:

- Age < 18 years

Locations and Contacts

Additional Information

Starting date: January 2006
Last updated: September 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017